Qualigen Therapeutics Inc
QLGN
Company Profile
Business description
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.
Contact
5857 Owens Avenue
Suite 300
CarlsbadCA92008
USAT: +1 760 452-8111
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
4
Stocks News & Analysis
stocks
Chart of the Week: The market may be underestimating Amcor’s long term potential
Our latest stock pitch.
stocks
Competitive pressures highlight need to lower costs for big 4 bank
Market reacts positively to results.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,907.00 | 2.50 | 0.03% |
| CAC 40 | 8,124.71 | 107.78 | -1.31% |
| DAX 40 | 23,673.07 | 368.55 | -1.53% |
| Dow JONES (US) | 47,457.22 | 797.60 | -1.65% |
| FTSE 100 | 9,651.21 | 156.47 | -1.60% |
| HKSE | 26,572.46 | 500.57 | -1.85% |
| NASDAQ | 22,870.36 | 536.10 | -2.29% |
| Nikkei 225 | 50,376.53 | 905.30 | -1.77% |
| NZX 50 Index | 13,464.46 | 133.41 | -0.98% |
| S&P 500 | 6,737.49 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,634.50 | 8.90 | 0.10% |
| SSE Composite Index | 3,990.49 | 39.01 | -0.97% |